Crashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minutePC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11A falling share price is not proof that a stock is cheap—or that it will rebound. The available examples do not support a current, comparable list of seven stocks to buy, so the useful way to approach “beaten-down stocks” is to test the decline, the business, its finances and its valuation before considering a recovery thesis. The names below are dated leads to investigate, not recommendations.
What “beaten-down” means—and what it doesn’t
“Beaten-down” describes a stock whose price has declined over a specified period. It is not an official valuation category, and the label alone says nothing about whether the shares are undervalued. A price can fall because investors have overreacted—or because the company’s prospects have genuinely worsened.
Motley Fool contributor Prosper Junior Bakiny captured the distinction in a September 8, 2026 article: “Buying a stock that has significantly lagged broader equities is only a good idea when there are solid reasons to expect it will bounce back and perform better over the long run.” A rebound thesis needs support from the company’s outlook, not just a chart showing a decline.
Why these seven examples are not a current buy list
The available coverage names several stocks that had fallen at different times and over different windows. It does not establish seven candidates on one current screen, with comparable drawdowns, verified company fundamentals and current valuations. A percentage decline measured from a 52-week high is not comparable to a year-to-date decline or a three-month return.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →#1 Best Overall
So the following are examples to re-check, not a ranked portfolio. Their cited declines and commentary belong to their publishers and publication dates; prices and conditions may have changed since then.
| Stock | What the cited article reported | What to investigate |
|---|---|---|
| Shopify (SHOP) | Motley Fool reported the shares were down 19% “this year” in its September 22, 2026 article, while arguing for the company’s long-term prospects. | Check the current price and operating results, then test whether growth and execution can support the valuation. |
| Intuitive Surgical (ISRG) | Motley Fool reported the shares were down 29% “this year” in the same September 22, 2026 article, while arguing for long-term prospects. | Review current results, guidance and valuation assumptions; a dated price decline does not establish a bargain. |
| TransMedics Group (TMDX) | Motley Fool reported a 28% decline over the prior year in its September 15, 2026 article and noted investment-related effects on margins. | Assess what those investments mean for margins, cash generation and the company’s operating trajectory. |
| SoFi Technologies (SOFI) | Motley Fool reported a 34% decline over the prior year in the same September 15, 2026 article and noted near-term outlook uncertainty. | Examine current guidance, financial health and whether the uncertainty has eased or deepened. |
| Rivian (RIVN) | Motley Fool’s September 16, 2026 article described a meaningful decline from the 52-week high and cited execution and competition risks; it did not provide a precise comparable percentage in the available material. | Look for evidence on execution and competitive position, and define what would invalidate a recovery case. |
| Robinhood (HOOD) | The same September 16, 2026 article described a meaningful decline from the 52-week high and cited product diversification and crypto volatility; it did not provide a precise comparable percentage in the available material. | Evaluate whether diversification is progressing and how exposed results remain to crypto-market swings. |
| Teladoc (TDOC) and Recursion Pharmaceuticals (RXRX) | In a September 8, 2026 article, Motley Fool argued that the outlooks did not justify buying the dip. | These are counterexamples to the assumption that every large decline is an opportunity: scrutinize the outlook before treating a lower price as a catalyst. |
The September articles offer different measurement windows and editorial judgments, not a unified screen. Do not compare the reported percentages as though they were calculated from the same dates or use them to infer which stock has the best prospective return.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
How to screen a beaten-down stock
Before comparing candidates, define the universe and the measurement rules. For a U.S.-equity screen, state the eligible market and currency, any liquidity or market-cap minimum, the drawdown reference and the cutoff date. Then assess each company on the same basis.
- Measure the decline consistently. Specify whether it is from a dated high, the start of the year or another reference point, and give the measurement date. Ask whether the decline reflects ordinary volatility or evidence of lasting business impairment.
- Choose and explain a valuation measure. Use a stated approach—such as a price-to-earnings multiple, free-cash-flow yield or price relative to an estimated fair value. Compare it with relevant peers or the company’s own history, and disclose the assumptions that make the comparison meaningful.
- Test business quality. Examine competitive position, durable demand, cash generation and management’s execution. A low multiple is not a substitute for a resilient business.
- Check financial health. Review debt maturities, liquidity, refinancing exposure and, where relevant, cash runway. Debt, dilution or limited liquidity can make a declining share price more dangerous, not more attractive.
- Identify the reason for the selloff. Connect the price move to current operating performance and the specific issue investors are reacting to. A recovery case should explain how that issue could improve.
- Set a catalyst and a failure test. Name the observable development that could support recovery and the measurable evidence that would show the thesis is wrong. Without both, “it has fallen a lot” is not an investment case.
What analyst screens and targets can—and can’t—tell you
Morningstar describes a long-term value screen that combines value-style classification with firms on its Best Companies to Own list—characterized by wide economic moats, predictable cash flows and management capital allocation—and compares share prices with its fair-value estimates. Its July 14, 2026 list named Campbell’s (CPB), Zoetis (ZTS), Yum China (YUMC), Clorox (CLX), Tractor Supply (TSCO), Sony (SONY), Microsoft (MSFT), Zimmer Biomet (ZBH), GE HealthCare (GEHC) and Reckitt Benckiser (RBGLY). This is an analyst value screen, not evidence that those stocks had recently fallen under one common definition of “beaten-down.”
Recommended Free Tools
Morningstar’s January 9, 2026 outlook said its U.S. equity coverage traded at a 4% discount to its composite fair-value estimates as of December 31, 2025. That is a dated, market-wide comparison using Morningstar’s estimates; it neither shows that every stock was cheap nor identifies a particular stock to buy.
Similarly, Investing.com’s InvestingPro analysis dated September 8, 2026 reported that its screen found eight stocks down 30.1%–42.5% over three months. The screen’s model fair-value estimates implied 29.1%–57.9% upside, while analyst targets implied 36.6%–127.7% upside. Those are estimates and target-based calculations attributed to that screen, not forecasts of realized returns. The available result did not reliably establish the individual names, so those ranges cannot provide a seven-stock list.
Rank #4
Fair-value models and analyst targets depend on assumptions that can be wrong. Treat them as inputs to investigate, not promises that a stock will recover.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Verify the company before acting
For any candidate, compare the price and valuation with the latest information from the company, rather than relying on an older commentary article. Review its latest SEC filing, earnings release and guidance, cash and debt position, and share count for dilution. Confirm the price date and use one consistent valuation method across the names being compared.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
A lower price can reflect durable deterioration: lost competitiveness, weaker demand, mounting debt, dilution, cyclicality or governance problems. If the company’s finances or operating outlook have worsened, the original price may no longer be a sensible reference point.
How to read “seven stocks” lists responsibly
A credible list should show its screen, not just its picks. It should make clear how it defined the universe, drawdown period and cutoff date; use comparable valuation measures; explain each company’s recovery case and the risks that could defeat it; and say what new evidence would change the view. Without those details, a set of lagging stocks is a collection of examples, not a validated buy list.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
